Bristol Myers Squibb is committed to helping appropriate patients get access to our
medications by providing access and reimbursement support services.

This information is intended for U.S. healthcare professionals and/or healthcare professionals involved in healthcare reimbursement.

Medication Selector >

OPDUALAG™
(nivolumab and relatlimab-rmbw)

Charitable Foundations
Resource

OpdualagM
Sample Claim Forms — Tutorial

CMS-1500

UB-04/CMS-1450

Download

Office Support Tool

Medical Necessity Template Letter*
Download

*Template letters are provided as examples of potential correspondence.

Find Local Care Resources for
Your Patients

Help patients find transportation, medical services, care at home, and other healthcare-related resources.

Formulary Large Icon Go to Patient Resource Connections
 

This site is operated by a third party and is not affiliated with Bristol Myers Squibb.

See Payer Policy Details

Learn about payer information by state for applicable treatments

Formulary Large Icon Start Here >

Billing and
Diagnosis Codes

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Reimbursement and Coding Guide for OPDUALAG
Download

  • Codes*
  • Distribution
  • FDA Letters
Filter by keyword Clear Filter
Type a keyword to find a specific HCPCS, CPT, NDC, or ICD-10 code
Healthcare Common Procedure Coding System (HCPCS) Codes1 Issued by CMS
J9298

COPY

Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg

Revenue Codes (for Use in the Hospital Outpatient Setting)2
0636

COPY

Drugs requiring detailed coding

0335

COPY

Chemotherapy administration, IV

0260

COPY

IV Therapy-General

Current Procedural Terminology (CPT)3,†
96413

COPY

Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

National Drug Codes (NDC)4 Issued by the FDA

Note:Payers require the submission of the 11-digit NDC on healthcare claim forms. Please use the 11-digit codes shown here.

00003-7125-11

COPY

A single-dose vial containing 240 mg of nivolumab and 80 mg of relatlimab per 20 mL (12 mg and 4 mg per mL) per carton

International Classification of Diseases, Tenth Revision, Clinical Modification Diagnosis Codes (ICD-10-CM)5
C43

COPY

Malignant melanoma of skin

C43.0

COPY

Malignant melanoma of lip

C43.1‡

COPY

Malignant melanoma of eyelid, including canthus

C43.10

COPY

Malignant melanoma of unspecified eyelid, including canthus

C43.11‡

COPY

Malignant melanoma of right eyelid, including canthus

C43.111

COPY

Malignant melanoma of right upper eyelid, including canthus

C43.112

COPY

Malignant melanoma of right lower eyelid, including canthus

C43.12‡

COPY

Malignant melanoma of left eyelid, including canthus

C43.121

COPY

Malignant melanoma of left upper eyelid, including canthus

C43.122

COPY

Malignant melanoma of left lower eyelid, including canthus

C43.2‡

COPY

Malignant melanoma of ear and external auricular canal

C43.20

COPY

Malignant melanoma of unspecified ear and external auricular canal

C43.21

COPY

Malignant melanoma of right ear and external auricular canal

C43.22

COPY

Malignant melanoma of left ear and external auricular canal

C43.3‡

COPY

Malignant melanoma of other and unspecified parts of face

C43.30

COPY

Malignant melanoma of unspecified part of face

C43.31

COPY

Malignant melanoma of nose

C43.39

COPY

Malignant melanoma of other parts of face

C43.4

COPY

Malignant melanoma of scalp and neck

C43.5‡

COPY

Malignant melanoma of trunk

C43.51

COPY

Malignant melanoma of anal skin

C43.52

COPY

Malignant melanoma of skin of breast

C43.59

COPY

Malignant melanoma of other part of trunk

C43.6‡

COPY

Malignant melanoma of upper limb, including shoulder

C43.60

COPY

Malignant melanoma of unspecified upper limb, including shoulder

C43.61

COPY

Malignant melanoma of right upper limb, including shoulder

C43.62

COPY

Malignant melanoma of left upper limb, including shoulder

C43.7‡

COPY

Malignant melanoma of lower limb, including hip

C43.70

COPY

Malignant melanoma of unspecified lower limb, including hip

C43.71

COPY

Malignant melanoma of right lower limb, including hip

C43.72

COPY

Malignant melanoma of left lower limb, including hip

C43.8

COPY

Malignant melanoma of overlapping sites of skin

C43.9

COPY

Malignant melanoma of skin, unspecified

C21

COPY

Malignant neoplasm of anus and anal canal

C21.0

COPY

Malignant neoplasm of anus, unspecified

C21.1

COPY

Malignant neoplasm of anal canal

C51

COPY

Malignant neoplasm of vulva

C51.0

COPY

Malignant neoplasm of labium majus

C51.1

COPY

Malignant neoplasm of labium minus

C51.2

COPY

Malignant neoplasm of clitoris

C51.9

COPY

Malignant neoplasm of vulva, unspecified

C52

COPY

Malignant neoplasm of vagina

C57

COPY

Malignant neoplasm of other and unspecified female genital organs

C57.7

COPY

Malignant neoplasm of other specified female genital organs

C57.8

COPY

Malignant neoplasm of overlapping sites of female genital organs

C57.9

COPY

Malignant neoplasm of female genital organ, unspecified

C60

COPY

Malignant neoplasm of penis

C60.0

COPY

Malignant neoplasm of prepuce

C60.1

COPY

Malignant neoplasm of glans penis

C60.8

COPY

Malignant neoplasm of overlapping sites of penis

C60.9

COPY

Malignant neoplasm of penis, unspecified

C63

COPY

Malignant neoplasm of other and unspecified male genital organs

C63.0‡

COPY

Malignant neoplasm of epididymis

C63.00

COPY

Malignant neoplasm of unspecified epididymis

C63.01

COPY

Malignant neoplasm of right epididymis

C63.02

COPY

Malignant neoplasm of left epididymis

C63.1‡

COPY

Malignant neoplasm of spermatic cord

C63.10

COPY

Malignant neoplasm of unspecified spermatic cord

C63.11

COPY

Malignant neoplasm of right spermatic cord

C63.12

COPY

Malignant neoplasm of left spermatic cord

C63.2

COPY

Malignant neoplasm of scrotum

C63.7

COPY

Malignant neoplasm of other specified male genital organs

C63.8

COPY

Malignant neoplasm of overlapping sites of male genital organs

C63.9

COPY

Malignant neoplasm of male genital organ, unspecified

Z51.12   

COPY

Encounter for antineoplastic immunotherapy 

Note: If infusion for antineoplastic immunotherapy is the only reason for the patient encounter, physicians and hospitals may report ICD-10-CM code “Z51.12 Encounter for antineoplastic immunotherapy” as the primary diagnosis.

OPDUALAG may be purchased through the distributors listed below.

Physician Offices

Authorized Distributor Phone Orders Fax Orders and Website
Cardinal Health Specialty Pharmaceutical Distribution 1-877-453-3972 https://specialty
online.cardinal
health.com
CuraScript Specialty Distribution 1-877-599-7748 https://www.
curascriptsd.
com
McKesson Specialty Health 1-800-482-6700 https://mscs.
mckesson.com
Morris & Dickson Specialty 1-800-710-6100 Fax: 1-318-524-3096
https://www.mdspecialtydist.com
Oncology Supply 1-800-633-7555 https://www.
oncologysupply.
com

For offices that prefer to use the services of a specialty pharmacy, specialty pharmacies can obtain OPDUALAG from the distributors listed above.

Hospitals and Infusion Centers

Specialty Distributor Phone Orders Fax Orders and Website
ASD Healthcare 1-800-746-6273 Fax: 1-800-547-9413
https://www.
asdhealthcare.
com
Cardinal Health Specialty Pharmaceutical Distribution 1-866-677-4844 Fax: 1-614-553-6301
https://order
express.cardinal
health.com
DMS Pharmaceutical Group, Inc. 1-877-788-1100 Fax: 1-847-518-1105
https://www.dms
pharma.com
McKesson Plasma and Biologics 1-877-625-2566 Fax: 1-888-752-7626
https://connect.
mckesson.com

Puerto Rico Hospitals and Clinics

Authorized Distributor Phone Orders Fax Orders and Website
Cardinal Puerto Rico (Borschow) 1-787-625-4200 https://orderexpress.cardinalhealth.com
Cesar Castillo, Inc. 1-787-641-5242 (Hospitals)
1-787-641-5082 (Specialty Pharmacies)		 Fax: 1-787-999-1614
https://www.facilfarmaciacci.com

Above information is accurate as of 08/22.

The OPDUALAG distribution program includes extended payment terms to Bristol Myers Squibb authorized OPDUALAG distributors. Healthcare providers and institutions should contact their OPDUALAG distributor to understand specific payment terms that may be available to them from their distributor.

Please see U.S. Full Prescribing Information for OPDUALAG.

FDA Approval Letter as Posted by the FDA:

OPDUALAG is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma – Approved on 03/18/2022

View Letter

Please see U.S. Full Prescribing Information for OPDUALAG.

Coding for OPDUALAG is dependent on the insurer and the care setting in which the drug will be administered. Oncology practices need to make coding decisions based on the diagnosis and treatment of each patient and the specific insurer requirements.

Please see U.S. Full Prescribing Information for OPDUALAG.

*Healthcare providers should code healthcare claims based upon the service that is rendered, the patient's medical record, the coding requirements of each health insurer, and best coding practices. Coding information provided under this heading does not provide a guarantee of reimbursement and should be considered together with all applicable coding guidance and standards. All of the coding information presented by this website is applicable to outpatient procedures only.

†CPT codes and descriptions only are ©2019 by American Medical Association (AMA). All rights reserved. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.

‡This is a category code and is invalid for stand-alone use.

References:

  1. American Medical Association. 2020 HCPCS Level II. Professional ed. Chicago, IL: American Medical Association; 2020.
  2. Palmetto GBA. Medicare Part A Billing Guide. May 2017. http://www.palmettogba.com/Palmetto/Providers.Nsf/files/ Part_A_Billing_Guide.pdf/$File/Part_A_Billing_Guide.pdf. Accessed August 17, 2022.
  3. American Medical Association. CPT Professional 2020. Professional ed. Chicago, IL: American Medical Association; 2019.
  4. OPDUALAG [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  5. Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. https://www.cms.gov/Medicare/Coding/ICD10/2020-ICD-10-CM. Accessed August 17, 2022.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Support Center icon
Support Center: 1-800-861-0048
8 am to 8 pm ET, Mon - Fri
Schedule a Call icon
Schedule a call from a Patient Access SpecialistSchedule a Call >
Request a Visit icon
Request a visit from a BMS Access & Reimbursement ManagerRequest a Visit >
Schedule a Call Request a Visit
BMS Logo

©2022 Bristol-Myers Squibb Company. Access Support is a registered trademark of Bristol-Myers Squibb Company.

Use of the information on this site is subject to the terms of our Legal Notice and Privacy Statement. The coding, coverage, and payment information contained within this website is current as of 03/22.

1425-US-2100039 03/22